Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B known ✓ | P08514 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5279548 | 1.00 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL5493238 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL3049211 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040497 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL2076614 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7863455 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL19240717 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL4363476 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL235394 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040501 | 0.98 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | MICROBIO (SHANGHAI) CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-117120576-A | Surface treatment agent, article, method for producing article, and compound | ＡＧＣ株式会社 | 2023-11-24 | — | — | CN | disclosed |
| CN-115996755-A | Bifunctional molecules and methods of use thereof | 旗舰创业创新VI有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115916262-A | Bifunctional molecules and methods of use thereof | 旗舰创业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022209489-A1 | LAMINATE AND METHOD FOR MANUFACTURING SAME | ＡＧＣ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022209502-A1 | SURFACE TREATMENT AGENT, ARTICLE, METHOD FOR PRODUCING ARTICLE, AND COMPOUND | ＡＧＣ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| CN-114206355-A | Methods and compositions for treating cancer with cancer-targeting adjuvants | 芝加哥大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20050192232-A1 | Novel acyl-dipeptide-like compounds bearing an accessory functional side chain spacer, a method for preparing the same and pharmaceutical compositions containing such products | OM PHARMA (CH) | 2005-09-01 | — | — | US | disclosed |
| EP-0702233-B1 | SIMPLE IMMUNOCHEMICAL SEMIQUANTITATIVE ASSAY METHOD AND APPARATUS | TEIKOKU HORMONE MFG CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6582970-B1 | Apparatus for use in the detection of preferential particles in sample | TEIKOKU HORMONE MFG. CO, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-6177281-B1 | DEVICE FOR THE EFFICIENT AND ACCURATE DETECTION AND ANALYSIS OF COMPOUNDS IN A SAMPLE | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0702233-A1 | SIMPLE IMMUNOCHEMICAL SEMIQUANTITATIVE ASSAY METHOD AND APPARATUS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1996-03-20 | — | — | EP | disclosed |
| EP-0010405-B1 | STABLE IMMUNOCHEMICAL ASSAY REAGENT FOR THE DETERMINATION OF HAPTENS, AND ASSAY METHOD USING SAID REAGENT | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1983-02-23 | — | — | EP | disclosed |
| US-4341758-A | Immunochemical assay reagent for the determination of haptens, and assay method therewith | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1982-07-27 | — | — | US | disclosed |
| EP-0010405-A1 | Stable immunochemical assay reagent for the determination of haptens, and assay method using said reagent | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192232-A1 | Novel acyl-dipeptide-like compounds bearing an accessory functional side chain spacer, a method for preparing the same and pharmaceutical compositions containing such products | PIGS, AADAT, CD74 | ITGB3 3432/4885ITGA2B 3340/4885HTT 3254/4885 |
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | GALNT1, CSGALNACT1, GALNT2 | ITGB3 504/4885ITGA2B 657/4885HTT 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.